Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.00001 per share (the "Shares")
Symbol
AARD on Nasdaq
Shares outstanding
21,303,054
Price per share
$13.35
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
10,747,406
Total reported value
$141,005,712
% of total 13F portfolios
0%
Share change
+850,529
Value change
+$11,023,600
Number of holders
65
Price from insider filings
$13.35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lee Tien-Li 14% $34,103,965 2,983,724 Tien-Li Lee 31 Mar 2025
Tan Finian 9.6% $23,441,810 2,050,902 Vickers Venture Fund VI Pte. Ltd. 12 Feb 2025
CITADEL ADVISORS LLC 5.6% $13,635,659 1,192,971 Kenneth Griffin 14 Feb 2025

As of 31 Dec 2025, 65 institutional investors reported holding 10,747,406 shares of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD). This represents 50% of the company’s total 21,303,054 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Decheng Capital LLC 18% 3,917,299 0% 6.9% $51,414,550
CITADEL ADVISORS LLC 6.1% 1,289,263 -5.2% 0.01% $16,921,577
Laurion Capital Management LP 4.8% 1,014,911 -3.3% 0.91% $13,320,707
BlackRock, Inc. 3.7% 784,430 +153% 0% $10,295,643
VANGUARD GROUP INC 3.4% 717,430 +29% 0% $9,416,269
MILLENNIUM MANAGEMENT LLC 2.3% 483,340 +51% 0% $6,343,838
SymBiosis Capital Partners, LLC 2.2% 476,595 0% 6.5% $6,255,309
SILVERARC CAPITAL MANAGEMENT, LLC 1.4% 303,939 -0.97% 0.58% $3,989,199
GEODE CAPITAL MANAGEMENT, LLC 1.4% 297,865 +54% 0% $3,910,348
STATE STREET CORP 0.74% 158,240 +70% 0% $2,076,900
TWO SIGMA INVESTMENTS, LP 0.6% 128,786 +103% 0% $1,690,316
Centiva Capital, LP 0.46% 97,520 0.08% $1,279,950
CANTOR FITZGERALD, L. P. 0.43% 91,682 -5.2% 0.04% $1,203,326
NORTHERN TRUST CORP 0.42% 89,298 +56% 0% $1,172,037
MORGAN STANLEY 0.37% 77,954 +14% 0% $1,023,146
SUPERSTRING CAPITAL MANAGEMENT LP 0.33% 69,496 0.49% $912,135
GOLDMAN SACHS GROUP INC 0.25% 53,349 +182% 0% $700,206
Schonfeld Strategic Advisors LLC 0.24% 50,131 -80% 0% $657,967
Propel Bio Management, LLC 0.22% 46,408 0.52% $609,105
Nuveen, LLC 0.19% 41,022 0% $538,414
Point72 Asset Management, L.P. 0.17% 36,922 0% $484,602
GSA CAPITAL PARTNERS LLP 0.17% 35,924 0.04% $472,000
Jump Financial, LLC 0.16% 34,575 0.01% $453,797
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.15% 31,533 +121% 0% $413,871
HRT FINANCIAL LP 0.15% 31,066 0% $407,000

Institutional Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 10,747,406 $141,005,712 +$11,023,600 $13.12 65
2025 Q3 9,460,972 $125,736,962 +$6,781,972 $13.29 48
2025 Q2 8,915,770 $120,541,916 +$8,913,830 $13.52 35
2025 Q1 8,686,452 $65,110,057 +$64,849,535 $7.51 27